

PRESS RELEASE

Lavipharm: Maintaining a strong presence on the global pharmaceutical stage with its 8th participation in CPHI Europe

Peania, 12.10.2026. With a clear and consistent focus on expanding its international business, Lavipharm has concluded its **8th participation in CPHI Europe**, the leading international gathering of the pharmaceutical industry, held this year in Milan from **October 6 to 8**.

Once again, the exhibition brought together the global pharmaceutical ecosystem, attracting more than **2,900 exhibiting companies**, over **62,000 industry professionals** and more than **320 expert speakers**. CPHI has long served as a key platform for networking and developing business partnerships, exchanging expertise and keeping abreast of developments in the global pharmaceutical market.

For Lavipharm, this year's participation in CPHI reaffirmed its strategic commitment to the continued expansion of its international operations. The company's expertise and capabilities were at the forefront, with a particular emphasis on transdermal technology. Throughout the exhibition, Lavipharm's executives held substantive meetings with existing and prospective partners from a range of markets, fostering dialogue around new business opportunities.

Mr. Giannis Sarigiannidis, Chief Commercial Officer International at Lavipharm, stated: "Our participation in CPHI for the eighth consecutive year reaffirms our unwavering commitment to expanding our international business. With a presence in more than 40 countries, we remain firmly focused on international growth, innovation and value creation through strategic international partnerships that can support Lavipharm's continued growth and strengthen its position in the global pharmaceutical market".



From left to right: Petroula Batzakaki, Katerina Tsardaka, Telemaque Lavidas, Nikos Ladas, Ligia Panaiteescu, Panagiotis Vlachogiannis, Dimos Pourdalas, Vassia Regli, Marianna Zampeli, Alexandros Tsiomeneas, Kiki Harami, Roxani Skartsiouni

About Lavipharma

Lavipharma (ASE: LAVI) is a pharmaceutical company focused on developing and delivering innovative healthcare solutions that advance patient care. Founded in Greece in 1911 and listed on the Athens Stock Exchange since 1995, the company has a strong presence in prescription and over-the-counter medicines in its domestic market. Lavipharma is internationally recognized for its expertise in transdermal drug delivery systems (TDDS) and maintains a global footprint through products distributed worldwide. With more than 115 years of history, Lavipharma remains committed to helping people live longer, healthier lives.

**For further Information:
Corporate Communications
Vivienne Thomas**

Tel. +30 210 6691404

vthomas@lavipharma.com